Summary: ew research uncovers how tau pathology spreads and damages synapses in progressive supranuclear palsy (PSP). Using ...

FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

In the city of dreams, one family is trapped in a slow, waking nightmare. This isn’t a sudden story of loss; it’s a story of ...

“When she would fall in public, people just assumed she was drunk,” said Glenn. “One time she fell backwards on the steps and ...

Researchers from Asan Medical Center, one of South Korea's largest hospitals, have developed a generative AI model that can ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

Commercial real estate player and former Kislak President Jeffrey Wiener died July 9 after a long battle with progressive ...

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are both closely related sporadic parkinsonian disorders with tau pathology that share many clinical features, such as ...

So, let’s talk about faith. I’m no rabbi or scholar, and I’m not trying to write a religious work. But putting my thoughts ...

Epidemiology & Pathogenesis Progressive supranuclear palsy is the most frequent parkinsonian disorder after PD. Its prevalence increases with age. [62] The average annual incidence rate for PSP ...

In The Salt Path, Raynor Winn writes that she and her husband lost their home after investing a “substantial sum” into a ...

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.